An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with recombinant Human Albumin (rHA) when administered to Children in their Second Year of Life - NA

Sanofi-Pasteur MSD S.N.C.0 sites600 target enrollmentStarted: TBDLast updated: May 13, 2024

Conditions

Trial Snapshot

Phase: Phase 3
Status: Completed
Sponsor
Enrollment: 600

Study Overview Eligibility Criteria Investigators Records & Identifiers Similar Trials

Study Overview

Brief Summary

No summary available.

Study Design

Study Type: Interventional

Eligibility Criteria

Ages: 2 to 11 (—)

Inclusion Criteria

•1. Healthy subject of either gender
•2. Age from 12 to 22 months (from the 12 month birthday to one day prior to the 23rd month birthday),
•3. Negative clinical history of infection with measles, mumps, rubella, varicella or zoster,
•4. Informed consent form signed by the parent(s) or by legal representative according to the local regulations
•5. Parent(s) or legal representative able to attend all scheduled visits with the subject and to understand and comply with the study procedures (i.e. able to read and write).

Exclusion Criteria

•1. Recent (<= 3 days) history of febrile illness(defined as rectal temperature >= 38.0°C)
•2. Prior receipt of measles, mumps, rubella and/or varicella vaccination, either alone or in any combination
•3. Recent (<= 30 days) exposure to measles, mumps, rubella, varicella or zoster involving:
•continuous household contact, or,
•playmate contact (generally >1 hour of play indoors), or
•hospital contact (in same 2- to 4-bed room or adjacent beds in a large ward or face-to-face contact with an infectious staff member or subject), or
•contact with a newborn whose mother had onset of varicella 5 days or less before delivery or within 48 hours after delivery,
•4. Prior known sensitivity/allergy to any component of the vaccine including neomycin, sorbitol or gelatin, or true allergy to egg proteins (anaphylactic or anaphylactoid reaction after ingesting eggs)
•5. Severe chronic disease,
•6. Blood dyscrasias, leukaemia, lymphomas of any type, or other malignant neoplasms affecting the haematopoietic and lymphatic system
•7. Any severe thrombocytopenia or any other coagulation disorder that would contraindicate intramuscular injection
•8. Humoral or cellular (primary or acquired) immunodeficiency, including hypogammaglobulinemia and dysgammaglobulinemia and AIDS, or symptomatic HIV infection
•9. Current immunosuppressive therapy (including systemic corticosteroids given daily or on alternate days at >=20 mg/day prednisone equivalent during >=14 days within the past 30 days)
•10. Family history of congenital or hereditary immunodeficiency
•11. Hereditary problems of fructose intolerance
•12. Known personal history of encephalopathy, seizure disorder or progressive, evolving or unstable neurological condition,
•13. Known active tuberculosis
•14. Recent (<= 2 days) tuberculin test or scheduled tuberculin test through Visit 3
•15. Receipt of immunoglobulins or blood-derived products in the past 150 days
•16. Receipt of an inactivated vaccine in the past 14 days
•17. Receipt of a live vaccine in the past 28 days
•18. Any medical condition which, in the opinion of the investigator, might interfere with the evaluation of the study objectives.
•19. Participation to another clinical study in the past 30 day.;There are also a list of temporary contra-indications and a list of defenitive contra-indications to further vaccination. See protocol page 20 for the detailed list.

Investigators

Sponsor

Sanofi-Pasteur MSD S.N.C.

Similar Trials

Active, not recruiting

Not Applicable

An Open-label, Multi-centre Study of the Safety of a 2-dose Regimen of a Combined Measles, Mumps, Rubella and Varicella Live Vaccine (ProQuad®) Manufactured with Recombinant Human Albumin (rHA) when administered to Children in their Second Year of LifeCombined Measles, Mumps, Rubella and Varicella Live VaccineMedDRA version: 9.1Level: LLTClassification code 10000639Term: Active immunisationMedDRA version: 9.1Level: LLTClassification code 10039242Term: Routine childhood immunisationMedDRA version: 9.1Level: LLTClassification code 10036897Term: Prophylactic vaccination

EUCTR2007-002438-12-SESanofi Pasteur MSD S.N.C.3,340

Active, not recruiting

Phase 1

EUCTR2007-002438-12-GRSanofi Pasteur MSD S.N.C.3,388

Active, not recruiting

Phase 1

EUCTR2007-002438-12-DKSanofi Pasteur MSD S.N.C.3,388

Active, not recruiting

Not Applicable

EUCTR2007-002438-12-DESanofi Pasteur MSD S.N.C.3,340

Active, not recruiting

Not Applicable

EUCTR2007-002438-12-NLSanofi Pasteur MSD S.N.C.3,340